To test whether the oncogenic function of APLN depends on PI3K/Akt activation, HCC cells with or without ectopic expression of APLN were treated with PI3K/Akt inhibitors BYL-719 and GDC-0941. The gene discussed is AKT1; the disease is hepatocellular carcinoma.